If obesity is a threat to your health and well-being; then weight
loss is a priority. Obesity is not just being overweight. Obesity
is assessed by the BMI count i.e. Body Mass Index. If the BMI count
exceeds 30, then the patient is clinically diagnosed with obesity.
Obesity can cause many related diseases like hypertension, high
cholesterol, diabetes, etc. Another vice that can take a toll on
your health is smoking. Smoking has been the most threatening factor
for causing respiratory problems and fatal illness like cancer.
Acomplia
Weight Loss Diet Pills |
|
PRODUCT |
QUANTITY |
PRICE(£) |
ORDER |
|
Acomplia 20 MG |
28 |
£128 |
|
Acomplia
20 MG |
56 |
£245 |
|
Acomplia
20 MG |
84 |
£362 |
|
As a large population of the world is affected by obesity and
smoking, the French pharmaceutical giant Sanofi-Aventis has introduced
a revolutionary drug Acomplia
(Rimonabant) or Zimulti which works as a diet pill as well
as a smoking cessation drug.
Zimulti
(Rimonabant), which works with the help of the active
ingredient Rimonabant (Acomplia), initiates weight loss
by blocking the CB-1 receptors found in the Endo-cannabinoid
(EC) system. Zimulti (Acomplia) works by targeting
these receptors, thereby, regulating your appetite and managing
hunger pangs. Zimulti (Rimonabant) when used in conjunction with
balanced diet, regular exercise and behavior alteration can prove
to be an exemplary drug for weight loss with additional benefits
of smoking cessation.
Zimulti (Acomplia) is strictly recommended to be used under prescription
and in consultation with your doctor so as to ward off side effects
and possible drug interactions. This diet pill should not be used
by pregnant women and lactating mothers. Moreover, Zimulti should
be strictly kept away from the reach of children.
Acomplia
Revolutionary weight loss drug acomplia (Rimonabant)
still has to make a lot of efforts to prove its mettle for sale
in the untied states as the U.S. Food and drug administration panel
clearly voted out the odds of drug being marketed as Zimulti
in the United States on June 13th. In an unambiguous decision,
the FDA's advisory panel finally rebuffed the French drug maker
Sanofi-Aventis's appeal to approve its diet pills to be sold under
the new name "Zimulti" in the U.S. citing safety concerns.
Based on the data provided by the maker for review last year, the
FDA's advisory panel aired a number of concerns over the safety
of acomplia diet pills, particularity about its effects on one's
psychological well-being.
In addition to available data on the safety of the weight loss drug,
the panel also considered reports pertaining to the adverse effects
of acomplia as to make an impartial decision.
Zimulti/Acomplia Treatment
Put an end to obesity with Zimulti treatment. Zimulti is an intended
name for Rimonabant for its launch in the US. It is basically an
anti-obesity drug.
It can give respite to people those who have a BMI (Body Mass
Index) greater than 30. BMI is a calculated value of your height
in proportion to your weight. A high BMI level, increases your chances
to be prone to health related issues like high blood pressure, type
2 diabetes, heart attack amongst others.
Zimulti drug causes weight reduction, a customary dosage of Zimulti
is considered similar to that of Acomplia dosage which is 20mg.
It is to be swallowed in one gulp with a full glass of water. This
pill is to be consumed in conjunction with a low-calorie diet and
regular exercises.
Do not overdose. Incase, you miss a dosage take it as soon as
you remember. If it is time for your next dosage, then continue
with your scheduled dosage. Prior consultation with your doctor
is recommended before embarking upon Zimulti treatment.
Pregnant women and breast-feeding mothers should avoid the consumption
of Zimulti diet drug. Your doctor should also be made aware of your
medical history or any medication you were or are engaged in, to
avoid contraindication of Zimulti (Acomplia) treatment.
Rimonabant (Acomplia) is available for purchase
by prescription in Europe under the name acomplia. |
